Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:

Surface Oncology Inc (SURF)

Surface Oncology Inc (SURF)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Help
Go To:
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BG, SURF, KLR PR Newswire - Tue Aug 29, 2023

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

BG : 82.62 (-1.67%)
SURF : 1.0700 (-0.93%)
KLR : 7.24 (-0.14%)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates NEX, TALS, QUOT, SURF PR Newswire - Mon Aug 7, 2023

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

NEX : 10.61 (+0.95%)
TALS : 27.20 (-0.73%)
QUOT : 3.99 (unch)
SURF : 1.0700 (-0.93%)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SURF, RETA, INPX PR Newswire - Fri Jul 28, 2023

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

SURF : 1.0700 (-0.93%)
RETA : 172.36 (+0.02%)
INPX : 5.2700 (-11.13%)
IMPORTANT ALERT: Halper Sadeh LLC Investigates TALS, SURF, NEX, CIR PR Newswire - Thu Jun 22, 2023

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

TALS : 27.20 (-0.73%)
SURF : 1.0700 (-0.93%)
NEX : 10.61 (+0.95%)
CIR : 56.00 (+5.16%)
Moore Kuehn Encourages SURF, NEX, NETI, and DICE Investors to Contact Law Firm PR Newswire - Tue Jun 20, 2023

/PRNewswire/ -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential...

SURF : 1.0700 (-0.93%)
NEX : 10.61 (+0.95%)
NETI : 11.33 (+0.09%)
DICE : 47.55 (+0.06%)
Shareholder Alert: Ademi LLP investigates whether Surface Oncology, Inc. has obtained a Fair Price in its transaction with Coherus PR Newswire - Fri Jun 16, 2023

/PRNewswire/ -- Ademi LLP is investigating Surface (Nasdaq: SURF) for possible breaches of fiduciary duty and other violations of law in its transaction with...

SURF : 1.0700 (-0.93%)
Surface Oncology Reports Financial Results and Business Highlights for Second Quarter 2022 Globe Newswire - Wed Aug 3, 2022

– SRF388 clinical data presented at 2022 ASCO Annual Meeting demonstrated monotherapy responses in two different indications, combination activity and...

SURF : 1.0700 (-0.93%)
Surface Oncology to Participate in the 2022 Wedbush PacGrow Healthcare Conference Globe Newswire - Mon Aug 1, 2022

CAMBRIDGE, Mass., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation...

SURF : 1.0700 (-0.93%)
Surface Oncology Appoints Carsten Brunn to Board of Directors Globe Newswire - Wed Jun 29, 2022

CAMBRIDGE, Mass., June 29, 2022 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation...

SURF : 1.0700 (-0.93%)
Surface Oncology Announces Publication of New Study Demonstrating the Role of the IL-27 Pathway in Hepatocellular Carcinoma Globe Newswire - Mon Jun 20, 2022

- Non-clinical findings further support the potential of SRF388 to treat patients suffering from liver cancer - CAMBRIDGE, Mass., June 20, 2022 (GLOBE...

SURF : 1.0700 (-0.93%)

Barchart Exclusives

Thanks to Wall Street, Novo Nordisk Stock is Now a Buy Barchart - Sat Nov 2, 10:15AM CDT
Novo Nordisk has lost about a quarter of its value since the end of June. Meanwhile, indications are that its diabetes and weight-loss drugs may be useful in fighting cardiovascular disease, arthritis, opioid and alcohol addiction, and Alzheimer's. Novo remains a leader in the sector, and is trading at a valuation a third cheaper than competitor, Eli Lilly. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot